Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. B, 1999, Pages 13-18

  Buxbaum, A ^a   Straschil, U ^a   Moser, C ^a   Graninger, W ^a   Georgopoulos, A ^a   Hirschl, A ^b   Wolf, D ^b   Ulrich, W ^b   Setinek Liszka, U ^b   Bibus, B ^b   Allerberger, F ^b   Sixl, B ^b   Thiel, W ^b   Muller M ^b   Grund, E ^b   Alpi, G ^b   Leitner, G ^b   Pflanzl, W ^b   Aichinger, W ^b   Feichtinger, J ^b   Gogl, H ^b   Brinninger, G ^b   Ohlinger W ^b   Gerstner, L ^b   Hudler, H ^b   Drlicek, M ^b   Bankl, H ^b   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; CONTROLLED STUDY; DILUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AUSTRIA; AZA COMPOUNDS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0032898032     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.suppl_2.13     Document Type: Article

References (46)

1. Loo, V. G., Lavellée, J., McAlear, D. & Robson, H. G. (1994). The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones. Journal of Antimicrobial Chemotherapy 33, 641-5.
2. Fenoll, A., Martin Bourgon, C., Munoz, R., Vicioso, D. & Casal, J. (1991). Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Reviews of Infectious Diseases 13, 56-60.
3. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs 49, Suppl. 2, 235-7.
4. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
5. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1996). MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrobial Agents and Chemotherapy 40, 362-6.
6. McDougal, L. K., Facklam, R., Reeves, M., Hunter, S., Swenson, J. M., Hill, B. C. et al. (1992). Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrobial Agents and Chemotherapy 36, 2176-84.
7. Munoz, R., Musser, J. M., Crain, M., Briles, D. E., Marton, A., Parkinson, A. J. et al. (1992). Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterisation by penicillin-binding protein profile, surface protein A typing, and multi-locus enzyme analysis. Clinical Infectious Diseases 15, 112-8.
8. Appelbaum, P. C. (1996). Emerging resistance to antimicrobial agents in Gram-positive bacteria. Pneumococci. Drugs 51, Suppl. 1, 1-5.
9. Ednie, L. M., Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1996). Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrobial Agents and Chemotherapy 40, 1950-2.
10. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 883-8.
11. Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J. et al. (1991). Infectious complications with respiratory pathogens despite ciprofloxacin therapy. New England Journal of Medicine 325, 520-1.
12. Barry, A. L., Fuchs, P. C. & Brown, S. D. (1996). In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrobial Agents and Chemotherapy 40, 2431-3.
13. Brueggemann, A. B., Kugler, K. C. & Doern, G. V. (1997). In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy 41, 1594-7.
14. Cruciani, M. & Bassetti, D. (1994). The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 33, 403-17.
15. Morrissey, I. & Smith, J. T. (1993). Activity of quinolone antibacterials against Streptococcus pneumoniae. Drugs 46, Suppl. 3, 196-7.
16. Perez-Trallero, E., Garcia-Arenzana, J. M., Jimenez, J. A. & Peris, A. (1990). Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 9, 905-6.
17. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing -Fifth Informational Supplement M100-S5. NCCLS, Wayne, PA.
18. Jacobs, M. R. (1992). Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 15, 119-27.
19. Goldstein, F. W. & Acar, J. F. (1995). Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49, Suppl. 2, 36-42.
20. Greenfield, R. A. (1993). Symposium on antimicrobial therapy. VII. The fluoroquinolones. Journal of the Oklahoma State Medical Association 86, 166-74.
21. Carbon, C. (1993). Quinolones in the treatment of lower respiratory tract infections in adult patients. Drugs 45, Suppl. 3, 91-7.
22. Eliopoulos, G. M. (1995). In vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 49, Suppl. 2, 48-57.
23. Eliopoulos, G. M. & Eliopoulos, C. T. (1993). Activity in vitro of the quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, D. S., Eds), pp. 161-93. American Society for Microbiology, Washington, DC.
24. Dalhoff, A. (1995). Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Drugs 49, Suppl. 2, 194-6.
25. Bongaerls, G. P. A. & Hoogkamp-Korstanje, J. A. A. (1993). In vitro activities of BAY y-3118, ciprofloxacin, ofloxacin, and fleroxacin against Gram-positive and Gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrobial Agents and Chemotherapy 37, 2017-9.
26. Reinert, R., Dalhoff, A., Schlaeger, J., Lemperle, M. & Lutticken, R. (1997). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F129. American Society for Microbiology, Washington, DC.
27. Rouse, M. S., Piper, K. E., Patel, R., Wilson, W. R. & Steckelberg, J. M. (1997). In vitro and in vivo activity of ciprofloxacin, levofloxacin, sparfloxacin or BAY 12-8039 against penicillin-resistant Streptococcus pneumoniae. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. B3. American Society for Microbiology, Washington, DC.
28. Souli, M., Wennersten, C. B. & Eliopoulos, G. M. (1997). In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, against species representative of respiratory tract pathogens. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No.F126. American Society for Microbiology, Washington, DC.
29. Kayser, F. H., Santanam, P. & Huf, E. (1997). Susceptibilities of invasive pneumococcal strains against the methoxyquinolone BAY 12-8039 compared to other quinolones. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F130. American Society for Microbiology, Washington, DC.
30. Robson, H. G., Tremblay, J.-F., Loo, V. G., Lavellée, J. & McAlear, D. (1997). Comparative in vitro activity of trovafloxacin, BAY 12-8039 and clinafloxacin against penicillin-intermediate and resistant Streptococcus pneumoniae. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F135. American Society for Microbiology, Washington, DC.
31. Klugman, K. P. & Capper, T. (1997). Concentration dependent killing of antibiotic-resistant pneumococci by the 8-methoxy-quinolone moxifloxacin. Journal of Antimicrobial Chemotherapy 40, 797-802.
32. Garcia-Rodriguez, J., Trujillano, I., Fresnadillo, M. & Iglesias, H. (1997). In vitro activity of BAY 12-8039 against respiratory tract pathogens. In Program and Abstracts of the Twentieth International Congress of Chemotherapy, Sydney, Australia. Poster No. 3351.
33. Loza, E., Morosini, M. I., Almaraz, F., Negri, M. C. & Baquero, F. (1998). Comparative in vitro activity of moxifloxacin (BAY 12-8039) against respiratory tract pathogens. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, 1998. Poster No. E206. American Society for Microbiology, Washington, DC.
34. Hoogkamp-Korstanje, J. A. A. (1997). Activity of BAY 12-8039 against Gram-positive cocci. In Program and Abstracts of the Eighth European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, 1997. Poster No. P1153.
35. Felmingham, D., Bobbins, M. J., Leakey, A., Salman, H., Dencer, C., Clark, S. et al. (1997). In vitro activity of BAY 12-8039. In Program and Abstracts of the Eighth European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, 1997. Poster No. P1155.
36. Focht, J. (1998). In vitro activity of moxifloxacin compared with other fluoroquinolones against bacterial strains from upper and lower respiratory tract infections in general practice. In Program and Abstracts of the Eighth International Congress on Infectious Diseases, Boston, Massachusetts, 1998. Poster No. 13.004.
37. Fass, R. J. (1997). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrobial Agents and Chemotherapy 41, 1818-24.
38. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
39. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51.
40. Visalli, M., Jacobs, M. & Appelbaum, P. (1997). Antipneumococcal activity of BAY 12-8039 compared to other drugs by time-kill. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F133. American Society for Microbiology, Washington, DC.
41. Blondeau, J., Laskowski, R. & Vaughan, D. (1997). In vitro activity of BAY 12-8039, a novel fluoroquinolone antimicrobial agent. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F155. American Society for Microbiology, Washington, DC.
42. Kitzis, M. D., Gutmann, L., Acar, J. F. & Goldstein, F. W. (1998). Selection of one-step mutants of Streptococcus pneumoniae with grepafloxacin in comparison to other fluoroquinolones. In Program and Abstracts of the Eighth International Congress on Infectious Diseases, Boston, Massachusetts, 1998. Poster No. 12.005.
43. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1992). Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 38, 856-9.
44. Rouse, M. S., Piper, K. E., Potel, R., Wilson, W. R. & Steckelberg, J. M. (1996). In vitro and in vivo activity of BAY 12-8039 and trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Poster No. B45. American Society for Microbiology, Washington, DC.
45. Baquero, F. & Canton, R. (1996). In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 1-18.
46. Tarpay, M. M., Welch, D. F., Salari, H. & Marks, M. I. (1982). In vitro activity of antibiotics commonly used in the treatment of otitis media against Streptococcus pneumoniae isolates with different susceptibility to penicillin. Antimicrobial Agents and Chemotherapy 22, 145-7.